Abiopharma

🔍 Elashmawi Esam (Executive)

Company: LATTICE SEMICONDUCTOR CORP (LSCC)

Report Date: 2026-08-16

Detailed Transactions and Holdings:

• Sold 593 shares of Common Stock at $130.46 per share (Direct)
  Date: 2026-08-16 | Code: F | equity_swap_involved: 0 | shares_owned_after: 171,600.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 438 shares of Common Stock at $132.67 per share (Direct)
  Date: 2026-08-17 | Code: F | equity_swap_involved: 0 | shares_owned_after: 171,162.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,934 shares of Common Stock at $132.7906 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 169,228.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 1,898 shares of Common Stock at $133.7708 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 167,330.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 8,882 shares of Common Stock at $134.9523 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 158,448.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 1,828 shares of Common Stock at $135.8299 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 156,620.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 1,200 shares of Common Stock at $136.5928 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 155,420.00 | transaction_form_type: 4 | Footnotes: F2, F7

Footnotes:

• F1: These shares were retained by the Issuer in order to meet the tax withholding obligations of the Reporting Person in connection with the vesting of an installment of the restricted stock units. The amount retained by the Issuer was not in excess of the amount of the tax liability.
• F2: The transaction indicated was conducted under an approved 10b5-1 Plan, adoption date of referenced 10b5-1(c) plan is: 05-18-2026.
• F3: This transaction was executed in multiple trades at prices ranging from $132.2600 to $133.2500. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F4: This transaction was executed in multiple trades at prices ranging from $133.2800 to $134.2300. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F5: This transaction was executed in multiple trades at prices ranging from $134.2800 to $135.2700. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F6: This transaction was executed in multiple trades at prices ranging from $135.2800 to $136.2100. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• F7: This transaction was executed in multiple trades at prices ranging from $136.4300 to $136.9300. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.